|
US7189834B2
(en)
*
|
1993-05-11 |
2007-03-13 |
Marshall William E |
Oligoribonucleotides alert the immune system of animals to the imminence of microbial infection
|
|
US5849719A
(en)
*
|
1993-08-26 |
1998-12-15 |
The Regents Of The University Of California |
Method for treating allergic lung disease
|
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US7935675B1
(en)
|
1994-07-15 |
2011-05-03 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6239116B1
(en)
*
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6429199B1
(en)
*
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
|
GB2324093A
(en)
|
1996-01-04 |
1998-10-14 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
|
US20030078223A1
(en)
*
|
1996-01-30 |
2003-04-24 |
Eyal Raz |
Compositions and methods for modulating an immune response
|
|
ATE292980T1
(de)
*
|
1996-10-11 |
2005-04-15 |
Univ California |
Immunostimulierende oligonucleotidekonjugate
|
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
|
AU738513B2
(en)
|
1997-02-28 |
2001-09-20 |
University Of Iowa Research Foundation, The |
Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
|
|
US6406705B1
(en)
*
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
|
US6426334B1
(en)
|
1997-04-30 |
2002-07-30 |
Hybridon, Inc. |
Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
|
|
DE69838294T2
(de)
|
1997-05-20 |
2009-08-13 |
Ottawa Health Research Institute, Ottawa |
Verfahren zur Herstellung von Nukleinsäurekonstrukten
|
|
ATE432348T1
(de)
|
1997-06-06 |
2009-06-15 |
Univ California |
Inhibitoren von immunstimulatorischen dna sequenz aktivität
|
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
|
US20040006034A1
(en)
*
|
1998-06-05 |
2004-01-08 |
Eyal Raz |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
|
US7138384B1
(en)
|
1997-08-29 |
2006-11-21 |
The Regents Of The University Of California |
Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
|
|
EP1872786A1
(en)
*
|
1997-09-05 |
2008-01-02 |
The Regents of the University of California |
Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
|
|
GB9727262D0
(en)
*
|
1997-12-24 |
1998-02-25 |
Smithkline Beecham Biolog |
Vaccine
|
|
ES2284247T3
(es)
|
1998-04-03 |
2007-11-01 |
University Of Iowa Research Foundation |
Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
|
|
EP1078053B1
(en)
*
|
1998-05-14 |
2005-09-28 |
Coley Pharmaceutical GmbH |
METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
|
|
JP4860039B2
(ja)
|
1998-05-19 |
2012-01-25 |
リサーチ ディベロップメント ファンデーション |
トリテルペン組成物及びその使用法
|
|
ATE335510T1
(de)
*
|
1998-05-22 |
2006-09-15 |
Ottawa Health Research Inst |
Methoden und produkte zur induzierung mukosaler immunität
|
|
US6562798B1
(en)
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
|
DK1104306T3
(da)
|
1998-08-10 |
2006-05-22 |
Antigenics Inc |
Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
|
|
WO2000016804A1
(en)
*
|
1998-09-18 |
2000-03-30 |
Dynavax Technologies Corporation |
METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
|
|
EP1150710B1
(en)
*
|
1999-02-17 |
2010-04-21 |
Csl Limited |
Immunogenic complexes and methods relating thereto
|
|
JP2002537102A
(ja)
|
1999-02-26 |
2002-11-05 |
カイロン コーポレイション |
吸着された高分子および微粒子を有するミクロエマルジョン
|
|
AU2457100A
(en)
|
1999-02-26 |
2000-09-14 |
Chiron S.P.A. |
Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
|
|
WO2000061151A2
(en)
*
|
1999-04-12 |
2000-10-19 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
|
TR200103018T2
(tr)
*
|
1999-04-19 |
2002-02-21 |
Beecham Biologicals S.A. Smithkline |
İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
|
|
GB9908885D0
(en)
*
|
1999-04-19 |
1999-06-16 |
Smithkline Beecham Biolog |
Vccine
|
|
EP1196558A1
(fr)
*
|
1999-06-08 |
2002-04-17 |
Aventis Pasteur |
Oligonucleotide immunostimulant
|
|
FR2797263B1
(fr)
*
|
1999-08-06 |
2003-09-19 |
Pasteur Merieux Serums Vacc |
Oligonucleotide immunostimulant
|
|
GB9915204D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Smithkline Beecham Biolog |
Vaccine
|
|
ES2250151T3
(es)
*
|
1999-06-29 |
2006-04-16 |
Glaxosmithkline Biologicals S.A. |
Uso de cpg como adyuvante de vacuna contra vih.
|
|
US6514948B1
(en)
*
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
|
US7479285B1
(en)
|
1999-08-19 |
2009-01-20 |
Dynavax Technologies Corporation |
Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
|
|
UA77152C2
(en)
*
|
1999-09-25 |
2006-11-15 |
|
Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
|
|
US6949520B1
(en)
*
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
|
US7223398B1
(en)
|
1999-11-15 |
2007-05-29 |
Dynavax Technologies Corporation |
Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
|
|
WO2001051083A2
(en)
*
|
2000-01-13 |
2001-07-19 |
Antigenics Inc. |
Innate immunity-stimulating compositions of cpg and saponin and methods thereof
|
|
AU2001227889A1
(en)
*
|
2000-01-14 |
2001-07-24 |
The United States of America, represented by The Secretary, Department of Health & Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
WO2001055341A2
(en)
*
|
2000-01-31 |
2001-08-02 |
The Regents Of The University Of California |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
|
US7585847B2
(en)
*
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
|
WO2001062207A2
(en)
*
|
2000-02-23 |
2001-08-30 |
The Regents Of The University Of California |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
|
US20040131628A1
(en)
*
|
2000-03-08 |
2004-07-08 |
Bratzler Robert L. |
Nucleic acids for the treatment of disorders associated with microorganisms
|
|
US20020098199A1
(en)
|
2000-03-10 |
2002-07-25 |
Gary Van Nest |
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
|
|
US7157437B2
(en)
|
2000-03-10 |
2007-01-02 |
Dynavax Technologies Corporation |
Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
|
|
US7129222B2
(en)
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
|
US20010046967A1
(en)
|
2000-03-10 |
2001-11-29 |
Gary Van Nest |
Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
|
|
US7534772B2
(en)
|
2000-06-22 |
2009-05-19 |
University Of Iowa Research Foundation |
Methods for enhancing antibody-induced cell lysis and treating cancer
|
|
WO2002002172A1
(en)
*
|
2000-06-30 |
2002-01-10 |
Univ Jefferson |
Dna palindrome - oligoguanylic acid compositions and uses thereof
|
|
KR100917101B1
(ko)
*
|
2000-08-04 |
2009-09-15 |
도요 보세키 가부시키가이샤 |
플렉시블 금속적층체 및 그 제조방법
|
|
CA2419894A1
(en)
*
|
2000-09-15 |
2002-03-21 |
Coley Pharmaceutical Gmbh |
Process for high throughput screening of cpg-based immuno-agonist/antagonist
|
|
WO2002034771A2
(en)
|
2000-10-27 |
2002-05-02 |
Chiron Srl |
Nucleic acids and proteins from streptococcus groups a & b
|
|
WO2002069369A2
(en)
*
|
2000-12-08 |
2002-09-06 |
Coley Pharmaceutical Gmbh |
Cpg-like nucleic acids and methods of use thereof
|
|
AU2002231336B2
(en)
*
|
2000-12-27 |
2007-06-28 |
Surefire Medical, Inc. D/B/A Trisalus Life Sciences |
Immunomodulatory polynucleotides and methods of using the same
|
|
US20030050268A1
(en)
*
|
2001-03-29 |
2003-03-13 |
Krieg Arthur M. |
Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
|
|
EP1390495B1
(en)
|
2001-05-21 |
2007-07-04 |
Intercell AG |
Immunostimulatory oligodeoxynucleic molecules
|
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
|
AU2002345847B2
(en)
|
2001-06-21 |
2008-05-29 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same
|
|
JP4370161B2
(ja)
*
|
2001-06-29 |
2009-11-25 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
Ｈｃｖｅ１ｅ２ワクチン組成物
|
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
|
US7666674B2
(en)
|
2001-07-27 |
2010-02-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
|
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
|
WO2003012061A2
(en)
*
|
2001-08-01 |
2003-02-13 |
Coley Pharmaceutical Gmbh |
Methods and compositions relating to plasmacytoid dendritic cells
|
|
JP4607452B2
(ja)
*
|
2001-08-07 |
2011-01-05 |
ダイナバックス テクノロジーズ コーポレイション |
免疫調節性組成物、製剤およびその使用方法
|
|
US7354909B2
(en)
*
|
2001-08-14 |
2008-04-08 |
The United States Of America As Represented By Secretary Of The Department Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
|
US8834900B2
(en)
*
|
2001-08-17 |
2014-09-16 |
University Of Iowa Research Foundation |
Combination motif immune stimulatory oligonucleotides with improved activity
|
|
DK1567641T3
(da)
|
2001-08-24 |
2012-08-27 |
Uvic Industry Partnerships Inc |
Proaerolysin indeholdende proteaseaktiveringssekvenser og fremgangsmåder til anvendelse til behandling af prostatacancer.
|
|
CN1575184A
(zh)
*
|
2001-09-07 |
2005-02-02 |
波士顿大学理事会 |
治疗免疫复合物相关疾病的方法和组合物
|
|
ATE447967T1
(de)
|
2001-09-14 |
2009-11-15 |
Cytos Biotechnology Ag |
Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
|
|
US7514415B2
(en)
|
2002-08-01 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
|
|
US7514414B2
(en)
*
|
2001-09-24 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Suppressors of CpG oligonucleotides and methods of use
|
|
US20030119774A1
(en)
*
|
2001-09-25 |
2003-06-26 |
Marianna Foldvari |
Compositions and methods for stimulating an immune response
|
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
|
CA2461315A1
(en)
*
|
2001-10-05 |
2003-04-17 |
Coley Pharmaceutical Gmbh |
Toll-like receptor 3 signaling agonists and antagonists
|
|
EP1478371A4
(en)
*
|
2001-10-12 |
2007-11-07 |
Univ Iowa Res Found |
METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
|
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
|
US8466116B2
(en)
|
2001-12-20 |
2013-06-18 |
The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce epithelial cell growth
|
|
EP1531796B1
(en)
|
2002-02-20 |
2016-09-28 |
GlaxoSmithKline Biologicals SA |
Microparticles with adsorbed polypeptide-containing molecules
|
|
US8153141B2
(en)
*
|
2002-04-04 |
2012-04-10 |
Coley Pharmaceutical Gmbh |
Immunostimulatory G, U-containing oligoribonucleotides
|
|
KR100456681B1
(ko)
*
|
2002-05-22 |
2004-11-10 |
주식회사 대웅 |
박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
|
|
CA2388049A1
(en)
*
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
|
AU2003243409A1
(en)
*
|
2002-06-05 |
2003-12-22 |
Coley Pharmaceutical Group, Inc. |
Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
|
|
US7576066B2
(en)
*
|
2002-07-03 |
2009-08-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
|
US7605138B2
(en)
*
|
2002-07-03 |
2009-10-20 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
|
US7569553B2
(en)
*
|
2002-07-03 |
2009-08-04 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
|
US7807803B2
(en)
*
|
2002-07-03 |
2010-10-05 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
|
US20040053880A1
(en)
*
|
2002-07-03 |
2004-03-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
|
WO2004007743A2
(en)
*
|
2002-07-17 |
2004-01-22 |
Coley Pharmaceutical Gmbh |
Use of cpg nucleic acids in prion-disease
|
|
AU2003254585A1
(en)
|
2002-07-24 |
2004-02-16 |
Intercell Ag |
Antigens encoded by alternative reading frame from pathogenic viruses
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
RU2338750C2
(ru)
*
|
2002-08-19 |
2008-11-20 |
Коли Фармасьютикал Груп, Инк. |
ИММУНОСТИМУЛИРУЮЩИЕ ФОСФОРТИОАТНЫЕ CpG-ОЛИГОНУКЛЕОТИДЫ, СОДЕРЖАЩИЕ ФОСФОДИЭФИРНЫЕ СВЯЗИ, СПОСОБ ИММУНОМОДУЛЯЦИИ, СПОСОБ СТИМУЛИРОВАНИЯ ИММУННОГО ОТВЕТА
|
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
|
EP1537418A2
(en)
|
2002-09-13 |
2005-06-08 |
Intercell AG |
Method for isolating hepatitis c virus peptides
|
|
US8263091B2
(en)
*
|
2002-09-18 |
2012-09-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
|
|
US8043622B2
(en)
*
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
|
MXPA05004588A
(es)
*
|
2002-10-29 |
2005-12-14 |
Coley Pharmaceutical Group Ltd |
Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
|
|
US20040248837A1
(en)
*
|
2002-11-01 |
2004-12-09 |
Eyal Raz |
Methods of treating pulmonary fibrotic disorders
|
|
EP1572122A4
(en)
*
|
2002-11-01 |
2008-04-09 |
Us Gov Health & Human Serv |
METHOD FOR PREVENTING INFECTIONS OF BIOTERRORISM AGENTS WITH IMMUNOSTIMULATING CPG OLIGONUCLEOTIDES
|
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
|
US8039443B2
(en)
*
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US10100316B2
(en)
*
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20050124565A1
(en)
*
|
2002-11-21 |
2005-06-09 |
Diener John L. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
|
WO2004053104A2
(en)
|
2002-12-11 |
2004-06-24 |
Coley Pharmaceutical Group, Inc. |
5’ cpg nucleic acids and methods of use
|
|
US20040213808A1
(en)
*
|
2002-12-11 |
2004-10-28 |
Michael Lieberman |
Recombinant vaccine against flavivirus infection
|
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
|
PT1575977E
(pt)
|
2002-12-23 |
2009-12-15 |
Dynavax Tech Corp |
Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
|
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
|
DE602004029657D1
(de)
|
2003-03-24 |
2010-12-02 |
Intercell Ag |
Verbesserte impfstoffe
|
|
WO2004087203A2
(en)
*
|
2003-04-02 |
2004-10-14 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
|
EP2623601B1
(en)
|
2003-04-21 |
2015-02-18 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
WO2004100965A1
(ja)
*
|
2003-05-15 |
2004-11-25 |
Japan Science And Technology Agency |
免疫刺激剤
|
|
US7803386B2
(en)
|
2003-06-05 |
2010-09-28 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
|
|
MXPA05013922A
(es)
*
|
2003-06-20 |
2006-02-24 |
Coley Pharm Group Inc |
Antagonistas de receptor tipo toll de molecula pequena.
|
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
|
AU2004275876B2
(en)
*
|
2003-09-25 |
2011-03-31 |
Coley Pharmaceutical Gmbh |
Nucleic acid-lipophilic conjugates
|
|
BRPI0416079A
(pt)
*
|
2003-10-30 |
2007-01-02 |
Coley Pharm Gmbh |
análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada
|
|
US20050239733A1
(en)
*
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
|
US20050100983A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Coley Pharmaceutical Gmbh |
Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
|
|
US7973016B2
(en)
*
|
2004-01-23 |
2011-07-05 |
Joslin Diebetes Center |
Methods of treating, reducing, or preventing autoimmune conditions
|
|
TW200533750A
(en)
|
2004-02-19 |
2005-10-16 |
Coley Pharm Group Inc |
Immunostimulatory viral RNA oligonucleotides
|
|
US20060193821A1
(en)
*
|
2004-03-05 |
2006-08-31 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
|
RU2006135119A
(ru)
*
|
2004-03-05 |
2008-04-10 |
Аркемикс Корп. (Us) |
Аптамеры к семейству цитокинов il-12 человека и их применение в качестве лекарственных средств для аутоиммунных заболеваний
|
|
TWI235440B
(en)
*
|
2004-03-31 |
2005-07-01 |
Advanced Semiconductor Eng |
Method for making leadless semiconductor package
|
|
US7579450B2
(en)
*
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
|
US8895521B2
(en)
*
|
2004-05-06 |
2014-11-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the treatment of uveitis
|
|
KR20100018029A
(ko)
*
|
2004-07-18 |
2010-02-16 |
씨에스엘 리미티드 |
면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
|
|
ATE465173T1
(de)
|
2004-09-24 |
2010-05-15 |
Intercell Ag |
Verändertes vp-1capsidprotein von parvovirus b19
|
|
EP3312272B1
(en)
|
2004-10-08 |
2019-08-28 |
The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services |
Modulation of replicative fitness by using less frequently used synonymous codons
|
|
MY159370A
(en)
*
|
2004-10-20 |
2016-12-30 |
Coley Pharm Group Inc |
Semi-soft-class immunostimulatory oligonucleotides
|
|
EP3034089A1
(en)
|
2004-11-02 |
2016-06-22 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
|
DK2682126T3
(en)
|
2005-01-27 |
2017-02-27 |
Children's Hospital & Res Center At Oakland |
GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
|
|
WO2006091915A2
(en)
*
|
2005-02-24 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory oligonucleotides
|
|
EP1874325A2
(en)
*
|
2005-04-08 |
2008-01-09 |
Coley Pharmaceutical Group, Inc. |
Methods for treating infectious disease exacerbated asthma
|
|
WO2006116458A2
(en)
*
|
2005-04-26 |
2006-11-02 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhances immunostimulatory activity
|
|
EP1891093B1
(en)
|
2005-06-14 |
2011-03-23 |
Protox Therapeutics Incorporated |
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
|
|
AU2006265896B2
(en)
|
2005-06-30 |
2012-05-31 |
Archemix Corp. |
Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
|
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
|
DK2179737T3
(da)
*
|
2005-07-01 |
2013-11-11 |
Index Pharmaceuticals Ab |
Modulering af respons på steroider
|
|
DE602006015963D1
(de)
|
2005-07-01 |
2010-09-16 |
Index Pharmaceuticals Ab |
Immunstimulatorisches verfahren
|
|
CN101268101A
(zh)
*
|
2005-07-07 |
2008-09-17 |
科利制药集团公司 |
用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
|
|
WO2007008904A2
(en)
*
|
2005-07-08 |
2007-01-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
|
|
US20090306177A1
(en)
*
|
2005-09-16 |
2009-12-10 |
Coley Pharmaceutical Gmbh |
Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (Sirna) by Nucleotide Modification
|
|
JP2010503608A
(ja)
*
|
2005-09-16 |
2010-02-04 |
コーリー ファーマシューティカル ゲーエムベーハー |
ホスホジエステルバックボーンを有する免疫刺激性一本鎖リボ核酸
|
|
WO2007041190A2
(en)
*
|
2005-09-30 |
2007-04-12 |
The University Of Iowa Research Foundation |
Polymer-based delivery system for immunotherapy of cancer
|
|
AU2006306805A1
(en)
|
2005-10-28 |
2007-05-03 |
Index Pharmaceuticals Ab |
Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
|
|
WO2007062107A2
(en)
*
|
2005-11-25 |
2007-05-31 |
Coley Pharmaceutical Gmbh |
Immunostimulatory oligoribonucleotides
|
|
EP1973608A1
(en)
|
2005-12-14 |
2008-10-01 |
Cytos Biotechnology AG |
Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
|
|
EP1991678B2
(en)
*
|
2006-02-15 |
2020-07-15 |
Rechtsanwalt Thomas Beck |
Compositions and methods for oligonucleotide formulations
|
|
EP1994409A2
(en)
|
2006-03-14 |
2008-11-26 |
Oregon Health and Science University |
Methods for producing an immune response to tuberculosis
|
|
WO2007119815A1
(ja)
|
2006-04-14 |
2007-10-25 |
Kyowa Hakko Kirin Co., Ltd. |
Ｔｏｌｌ様受容体９作動薬
|
|
US20070243290A1
(en)
*
|
2006-04-18 |
2007-10-18 |
Melody Thompson |
Method of tailoring infant formulas to individual nutritional needs prior to use
|
|
NZ573622A
(en)
|
2006-06-12 |
2011-12-22 |
Cytos Biotechnology Ag |
Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
|
|
MX2009003398A
(es)
|
2006-09-27 |
2009-08-12 |
Coley Pharm Gmbh |
Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
|
|
US20100144846A1
(en)
*
|
2006-10-26 |
2010-06-10 |
Coley Pharmaceutical Gmbh |
Oligoribonucleotides and uses thereof
|
|
DK2078197T3
(en)
|
2006-11-01 |
2016-05-23 |
Ventana Med Syst Inc |
Haptenes, hapten conjugates, compositions thereof and processes for their preparation and use
|
|
US20090142362A1
(en)
*
|
2006-11-06 |
2009-06-04 |
Avant Immunotherapeutics, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
|
|
DK2918598T3
(en)
|
2007-02-28 |
2019-04-29 |
The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services |
Brachyury polypeptides and methods of use
|
|
CA2699190A1
(en)
|
2007-04-19 |
2009-10-30 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
|
|
US8518903B2
(en)
|
2007-04-19 |
2013-08-27 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of toll-like receptor-9 agonists
|
|
US8320302B2
(en)
|
2007-04-20 |
2012-11-27 |
Elster Electricity, Llc |
Over the air microcontroller flash memory updates
|
|
MX2009012482A
(es)
*
|
2007-05-17 |
2009-12-02 |
Coley Pharm Group Inc |
Oligonucleotidos de clase a con potencia inmunoestimuladora.
|
|
PT2170353E
(pt)
*
|
2007-05-18 |
2015-09-16 |
Adiutide Pharmaceuticals Gmbh |
Análogos de oligonucleotídeo modificados por fosfato com atividade imunoestimulante
|
|
EP3561513A1
(en)
|
2007-05-23 |
2019-10-30 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
|
JP2010527633A
(ja)
*
|
2007-05-25 |
2010-08-19 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
Ｔｏｌｌ様受容体３モジュレーター及びその使用
|
|
RU2010112771A
(ru)
*
|
2007-10-09 |
2011-11-20 |
Коули Фармасьютикал ГмбХ (DE) |
Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
|
|
WO2010008411A1
(en)
|
2007-11-09 |
2010-01-21 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
|
EP3067048B1
(en)
|
2007-12-07 |
2018-02-14 |
GlaxoSmithKline Biologicals SA |
Compositions for inducing immune responses
|
|
ES2557282T3
(es)
|
2008-03-10 |
2016-01-25 |
Children's Hospital & Research Center At Oakland |
Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
|
|
WO2009143292A2
(en)
|
2008-05-21 |
2009-11-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating pneumoconiosis with oligodeoxynucleotides
|
|
US8703490B2
(en)
|
2008-06-05 |
2014-04-22 |
Ventana Medical Systems, Inc. |
Compositions comprising nanomaterials and method for using such compositions for histochemical processes
|
|
SI3056214T1
(sl)
|
2008-06-27 |
2019-06-28 |
Zoetis Services Llc |
Nove pomožne sestavine
|
|
WO2010034007A2
(en)
|
2008-09-22 |
2010-03-25 |
Oregon Health & Science University |
Methods for detecting a mycobacterium tuberculosis infection
|
|
NZ601345A
(en)
|
2008-10-16 |
2014-05-30 |
Univ Dalhousie |
Combination adjuvant formulation
|
|
EP2865389A1
(en)
|
2008-12-09 |
2015-04-29 |
Pfizer Vaccines LLC |
IgE CH3 peptide vaccine
|
|
US8664183B2
(en)
|
2009-02-27 |
2014-03-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
SPANX-B polypeptides and their use
|
|
MX2011010050A
(es)
|
2009-03-25 |
2011-12-14 |
Univ Texas |
Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
|
|
KR101450958B1
(ko)
|
2009-04-30 |
2014-10-15 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
폐렴구균 백신 및 그의 용도
|
|
WO2010138193A2
(en)
|
2009-05-27 |
2010-12-02 |
Selecta Biosciences, Inc. |
Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
|
|
MX2012001194A
(es)
|
2009-07-30 |
2012-03-07 |
Pfizer Vaccines Llc |
Peptidos tau antigenicos y usos de los mismos.
|
|
WO2011022427A1
(en)
*
|
2009-08-18 |
2011-02-24 |
Archemix Corp. |
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
|
|
US8598327B2
(en)
|
2009-08-18 |
2013-12-03 |
Baxter International Inc. |
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
|
|
WO2011026111A1
(en)
|
2009-08-31 |
2011-03-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Oral delivery of a vaccine to the large intestine to induce mucosal immunity
|
|
ES2670576T3
(es)
|
2009-09-03 |
2018-05-31 |
Pfizer Vaccines Llc |
Vacuna de PCSK9
|
|
ES2594485T3
(es)
|
2009-10-07 |
2016-12-20 |
Uvic Industry Partnerships Inc. |
Vacunas que comprenden transgenes sensibles al calor
|
|
US9181306B2
(en)
|
2009-10-16 |
2015-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
|
CN102713629B
(zh)
|
2009-11-20 |
2016-02-24 |
俄勒冈健康科学大学 |
用于检测结核分枝杆菌感染的方法
|
|
WO2011077309A2
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Vaccines Llc |
Vaccine compositions
|
|
WO2011112599A2
(en)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Immunogenic pote peptides and methods of use
|
|
BR122021020829B8
(pt)
|
2010-03-30 |
2022-12-27 |
Children´S Hospital & Res Center At Oakland |
Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
|
|
TR201802741T4
(tr)
|
2010-05-14 |
2018-03-21 |
Univ Oregon Health & Science |
Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
|
|
US20110293700A1
(en)
|
2010-05-26 |
2011-12-01 |
Selecta Biosciences, Inc. |
Nanocarrier compositions with uncoupled adjuvant
|
|
EP2576613A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
|
CA2800774A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
|
AU2011302360B2
(en)
|
2010-09-14 |
2015-01-29 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for influenza
|
|
US9072760B2
(en)
|
2010-09-24 |
2015-07-07 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
|
|
US10668092B2
(en)
|
2010-09-24 |
2020-06-02 |
The John Hopkins University |
Compositions and methods for treatment of inflammatory disorders
|
|
EP2640190A4
(en)
|
2010-11-05 |
2016-05-11 |
Selecta Biosciences Inc |
MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
|
|
WO2012088425A2
(en)
|
2010-12-22 |
2012-06-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
|
|
EP2673364A1
(en)
|
2011-02-11 |
2013-12-18 |
Baxter International Inc |
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
|
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
|
WO2012142480A1
(en)
*
|
2011-04-14 |
2012-10-18 |
Beth Israel Deaconess Medical Center, Inc. |
Chimeric rna oligonucleotides and uses thereof
|
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
|
WO2012167046A1
(en)
|
2011-06-01 |
2012-12-06 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
|
AU2012262021B2
(en)
|
2011-06-01 |
2016-07-28 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
|
JP6113155B2
(ja)
|
2011-06-20 |
2017-04-12 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
|
|
CN109172819A
(zh)
|
2011-07-29 |
2019-01-11 |
西莱克塔生物科技公司 |
产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
|
|
WO2013039792A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunogens based on an hiv-1 gp120 v1v2 epitope
|
|
WO2013049535A2
(en)
|
2011-09-30 |
2013-04-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Influenza vaccine
|
|
CA2850932A1
(en)
|
2011-10-04 |
2013-04-11 |
Janus Biotherapeutics, Inc. |
Novel imidazole quinoline-based immune system modulators
|
|
US20140286983A1
(en)
|
2011-10-20 |
2014-09-25 |
The Government of the USA as represented by the Secretaryof the Dept. of Health and Human Services |
Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
|
|
AU2013209887B2
(en)
|
2012-01-16 |
2021-02-18 |
Elizabeth Mckenna |
Compositions and methods for the treatment of hepatic diseases and disorders
|
|
US12268718B2
(en)
|
2012-01-16 |
2025-04-08 |
Labyrinth Holdings Llc |
Control of cellular redox levels
|
|
RU2018113521A
(ru)
|
2012-02-07 |
2019-03-04 |
Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн |
Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b
|
|
EP3305806B1
(en)
|
2012-02-13 |
2020-08-26 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
|
|
WO2013142808A1
(en)
|
2012-03-23 |
2013-09-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
|
NZ701324A
(en)
|
2012-05-04 |
2016-09-30 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
EP2852405B1
(en)
|
2012-05-23 |
2019-03-13 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof
|
|
US9427476B2
(en)
|
2012-05-24 |
2016-08-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Multivalent meningococcal conjugates and methods for preparing conjugates
|
|
US9687542B2
(en)
|
2012-06-19 |
2017-06-27 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Rift valley fever virus replicon particles and use thereof
|
|
EP2895191B1
(en)
|
2012-09-14 |
2019-06-05 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
|
|
JP2015535829A
(ja)
|
2012-09-21 |
2015-12-17 |
マッケーナ、エリザベス |
天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
|
|
US9562066B2
(en)
*
|
2012-09-25 |
2017-02-07 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Oral therapy of necrotizing enterocolitis
|
|
WO2014172661A1
(en)
|
2013-04-19 |
2014-10-23 |
The Regent Of The University Of California |
Lone star virus
|
|
AU2014385320B2
(en)
|
2013-05-15 |
2019-10-10 |
The Governors Of The University Of Alberta |
E1E2 HCV vaccines and methods of use
|
|
WO2015042423A2
(en)
|
2013-09-19 |
2015-03-26 |
Zoetis Llc |
Vaccine
|
|
WO2015048785A2
(en)
|
2013-09-30 |
2015-04-02 |
Los Alamos National Security, Llc |
Mosaic conserved region hiv immunogenic polypeptides
|
|
KR102196884B1
(ko)
|
2013-11-01 |
2020-12-30 |
화이자 인코포레이티드 |
전립선-연관 항원의 발현을 위한 벡터
|
|
WO2015089469A1
(en)
|
2013-12-13 |
2015-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Multi-epitope tarp peptide vaccine and uses thereof
|
|
BR112016015835B1
(pt)
|
2014-01-21 |
2023-12-26 |
Pfizer Inc |
Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
|
|
CA2937190A1
(en)
|
2014-01-21 |
2015-07-30 |
Pfizer Inc. |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
KR20220080201A
(ko)
|
2014-01-21 |
2022-06-14 |
화이자 인코포레이티드 |
접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
|
|
US10279019B2
(en)
|
2014-02-11 |
2019-05-07 |
Stc.Unm |
PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
|
|
CA2986096A1
(en)
|
2014-05-30 |
2015-12-03 |
Sanofi Pasteur Inc. |
Expression and conformational analysis of engineered influenza hemagglutinin
|
|
US10434064B2
(en)
|
2014-06-04 |
2019-10-08 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
|
WO2016029077A1
(en)
|
2014-08-22 |
2016-02-25 |
Janus Biotherapeutics, Inc. |
Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
|
|
WO2016044839A2
(en)
|
2014-09-19 |
2016-03-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
|
DK3244917T5
(da)
|
2015-01-15 |
2024-10-14 |
Pfizer |
Immunogene sammensætninger til anvendelse i pneumokokvacciner
|
|
ES2950822T3
(es)
|
2015-01-16 |
2023-10-13 |
Zoetis Services Llc |
Vacuna contra la enfermedad de fiebre aftosa
|
|
WO2016131048A1
(en)
|
2015-02-13 |
2016-08-18 |
Icahn School Of Medicine At Mount Sinai |
Rna containing compositions and methods of their use
|
|
CA2987939A1
(en)
|
2015-06-02 |
2016-12-08 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
|
WO2016201224A1
(en)
|
2015-06-10 |
2016-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Processes for production and purification of nucleic acid-containing compositions
|
|
KR102800419B1
(ko)
|
2015-07-21 |
2025-04-25 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
|
US20190030153A1
(en)
|
2015-07-22 |
2019-01-31 |
University Of Saskatchewan |
Mycoplasma vaccines and uses thereof
|
|
EP4480544A3
(en)
|
2015-08-25 |
2025-03-26 |
Babita Agrawal |
Immunomodulatory compositions andmethods of use thereof
|
|
US10548970B2
(en)
|
2015-10-05 |
2020-02-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human rotavirus G9P[6] strain and use as a vaccine
|
|
US11186615B2
(en)
|
2015-10-08 |
2021-11-30 |
The Governors Of The University Of Alberta |
Hepatitis C virus E1/E2 heterodimers and methods of producing same
|
|
AU2016343845B2
(en)
|
2015-10-30 |
2023-04-13 |
Baylor College Of Medicine |
Compositions and methods for the treatment of HER2-expressing solid tumors
|
|
CA3005524C
(en)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
SG11201805621SA
(en)
|
2016-01-19 |
2018-08-30 |
Pfizer |
Cancer vaccines
|
|
WO2017189448A1
(en)
|
2016-04-25 |
2017-11-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bivalent immunogenic conjugate for malaria and typhoid
|
|
KR102617833B1
(ko)
|
2016-05-06 |
2023-12-27 |
엑시큐어 오퍼레이팅 컴퍼니 |
인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
|
|
US11173207B2
(en)
|
2016-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Adjuvant compositions
|
|
EP3464328A1
(en)
|
2016-06-02 |
2019-04-10 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
|
KR102731582B1
(ko)
|
2016-06-03 |
2024-11-15 |
사노피 파스퇴르 인코포레이티드 |
조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형
|
|
WO2017218339A1
(en)
|
2016-06-13 |
2017-12-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
|
|
US10632185B2
(en)
|
2016-07-08 |
2020-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric west nile/zika viruses and methods of use
|
|
CA3030154A1
(en)
|
2016-07-08 |
2018-01-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric dengue/zika viruses live-attenuated zika virus vaccines
|
|
CA3031797A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
KR102437120B1
(ko)
|
2016-08-05 |
2022-08-25 |
사노피 파스퇴르 인코포레이티드 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
US10172933B2
(en)
|
2016-10-31 |
2019-01-08 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Mosaic vaccines for serotype a foot-and-mouth disease virus
|
|
MX392525B
(es)
|
2017-01-20 |
2025-03-12 |
Pfizer |
Composiciones inmunogenicas para su uso en vacunas neumococicas
|
|
US11696954B2
(en)
|
2017-04-28 |
2023-07-11 |
Exicure Operating Company |
Synthesis of spherical nucleic acids using lipophilic moieties
|
|
US11464845B2
(en)
|
2017-07-21 |
2022-10-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neisseria meningitidis immunogenic compositions
|
|
WO2019090138A2
(en)
|
2017-11-04 |
2019-05-09 |
Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno |
Immunogenic conjugates and methods of use thereof
|
|
WO2019126197A1
(en)
|
2017-12-18 |
2019-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacterial polysaccharide-conjugated carrier proteins and use thereof
|
|
US11224648B2
(en)
|
2017-12-19 |
2022-01-18 |
Massachusetts Institute Of Technology |
Antigen-adjuvant coupling reagents and methods of use
|
|
WO2019143955A1
(en)
|
2018-01-22 |
2019-07-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly protective inactivated influenza virus vaccine
|
|
BR112020014978A2
(pt)
|
2018-02-05 |
2020-12-22 |
Sanofi Pasteur, Inc. |
Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
|
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
|
EP3774884B1
(en)
|
2018-03-28 |
2023-12-06 |
Sanofi Pasteur Inc. |
Methods of generating broadly protective vaccine compositions comprising hemagglutinin
|
|
CN112512567A
(zh)
|
2018-04-03 |
2021-03-16 |
赛诺菲 |
抗原性呼吸道合胞病毒多肽
|
|
JP2021519599A
(ja)
|
2018-04-03 |
2021-08-12 |
サノフイＳａｎｏｆｉ |
抗原性ｏｓｐａポリペプチド
|
|
JP2021519596A
(ja)
|
2018-04-03 |
2021-08-12 |
サノフイＳａｎｏｆｉ |
フェリチンタンパク質
|
|
EP3773708A2
(en)
|
2018-04-03 |
2021-02-17 |
Sanofi |
Antigenic epstein barr virus polypeptides
|
|
EP3773703A1
(en)
|
2018-04-03 |
2021-02-17 |
Sanofi |
Antigenic influenza-ferritin polypeptides
|
|
EP3820511A4
(en)
|
2018-07-13 |
2022-06-15 |
University of Georgia Research Foundation, Inc. |
INFLUENZA H3 VIRUS WIDELY REACTIVE IMMUNOGENS, COMPOSITIONS AND METHODS OF USE THE SAME
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
ES2993834T3
(en)
|
2018-12-04 |
2025-01-10 |
Univ Rockefeller |
Hiv vaccine immunogens
|
|
US20220023413A1
(en)
|
2018-12-12 |
2022-01-27 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
|
|
WO2020121159A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
|
US20220023410A1
(en)
|
2018-12-14 |
2022-01-27 |
University Of Georgia Research Foundation, Inc. |
Crimean-congo hemorrhagic fever virus replicon particles and use thereof
|
|
EP3946446A1
(en)
|
2019-04-02 |
2022-02-09 |
Sanofi |
Antigenic multimeric respiratory syncytial virus polypeptides
|
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
|
EP4438053A3
(en)
|
2019-09-18 |
2025-03-05 |
Children's Medical Center Corporation |
An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use
|
|
MX2022005252A
(es)
|
2019-11-01 |
2022-06-08 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
|
WO2021127271A1
(en)
|
2019-12-17 |
2021-06-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Live attenuated leishmania parasite vaccines with enhanced safety characteristics
|
|
CA3173729A1
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
JP2023515829A
(ja)
|
2020-02-28 |
2023-04-14 |
サノフィ パスツール インコーポレイテッド |
小児対象のための高用量インフルエンザワクチン
|
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
|
BR112022021258A2
(pt)
|
2020-04-20 |
2023-01-17 |
Univ Saskatchewan |
Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas
|
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
美商輝瑞大藥廠 |
大腸桿菌組合物及其方法
|
|
US12138302B2
(en)
|
2020-10-27 |
2024-11-12 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
EP4240410A1
(en)
|
2020-11-04 |
2023-09-13 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
CA3200968A1
(en)
|
2020-11-10 |
2022-05-19 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2022104006A2
(en)
*
|
2020-11-13 |
2022-05-19 |
Guardian Therapeutics, Llc |
Gpc3 aptamers and variants and use thereof
|
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
|
CN117425668A
(zh)
|
2021-03-16 |
2024-01-19 |
国立大学法人大阪大学 |
SARS-CoV-2病毒特异性滤泡辅助性T细胞Tfh
|
|
JPWO2022196701A1
(enExample)
|
2021-03-16 |
2022-09-22 |
|
|
|
WO2022249107A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
JP7714690B2
(ja)
|
2021-05-28 |
2025-07-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
AU2022311955A1
(en)
|
2021-07-16 |
2024-01-18 |
The Board Of Trustees Of The University Of Illinois |
Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
|
|
WO2023018817A1
(en)
|
2021-08-11 |
2023-02-16 |
Sanofi Pasteur Inc. |
Truncated influenza neuraminidase and methods of using the same
|
|
AU2022361432A1
(en)
|
2021-10-08 |
2024-05-23 |
Sanofi Pasteur Inc. |
Multivalent influenza vaccines
|
|
JP2024542085A
(ja)
|
2021-11-05 |
2024-11-13 |
サノフイ |
呼吸器合胞体ウイルスｒｎａワクチン
|
|
AU2022379948A1
(en)
|
2021-11-05 |
2024-06-20 |
Sanofi Pasteur Inc. |
Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
|
|
CA3237139A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi |
Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
|
|
CN118302191A
(zh)
|
2021-11-30 |
2024-07-05 |
圣诺菲·帕斯图尔公司 |
基于病毒载体的人偏肺病毒疫苗
|
|
US20230310571A1
(en)
|
2021-11-30 |
2023-10-05 |
Sanofi Pasteur Inc. |
Human metapneumovirus vaccines
|
|
WO2023111262A1
(en)
|
2021-12-17 |
2023-06-22 |
Sanofi |
Lyme disease rna vaccine
|
|
MX2024008039A
(es)
|
2022-01-13 |
2024-07-10 |
Pfizer |
Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos.
|
|
CN118591621A
(zh)
|
2022-01-27 |
2024-09-03 |
赛诺菲巴斯德有限公司 |
修饰的Vero细胞及其用于病毒生产的方法
|
|
US20250163484A1
(en)
|
2022-02-25 |
2025-05-22 |
Pfizer Inc. |
Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
|
|
WO2023177577A1
(en)
|
2022-03-14 |
2023-09-21 |
Sanofi Pasteur Inc. |
Machine-learning techniques in protein design for vaccine generation
|
|
IL316761A
(en)
|
2022-05-06 |
2025-01-01 |
Sanofi Sa |
Marker sequences for nucleic acid vaccines
|
|
EP4522208A1
(en)
|
2022-05-11 |
2025-03-19 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
|
CN120152987A
(zh)
|
2022-11-04 |
2025-06-13 |
赛诺菲巴斯德有限公司 |
呼吸道合胞病毒rna疫苗接种
|
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
|
IL321062A
(en)
|
2022-11-22 |
2025-07-01 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
IL321069A
(en)
|
2022-12-01 |
2025-07-01 |
Pfizer |
Pneumococcal conjugate vaccine preparations
|
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|
|
IL320955A
(en)
|
2022-12-13 |
2025-07-01 |
Pfizer |
Immunogenic compounds and methods for generating an immune response against CLOSTRIDIIOIDES (CLOSTRIDIUM) DIFCILE
|
|
CN120475991A
(zh)
|
2022-12-20 |
2025-08-12 |
赛诺菲巴斯德有限公司 |
鼻病毒mRNA疫苗
|
|
WO2024163327A1
(en)
|
2023-01-30 |
2024-08-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
|
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
AR132053A1
(es)
|
2023-03-02 |
2025-05-21 |
Sanofi Pasteur |
Composiciones para su uso en el tratamiento de clamidia
|
|
AU2024246082A1
(en)
|
2023-03-30 |
2025-10-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
CN121057590A
(zh)
|
2023-04-14 |
2025-12-02 |
辉瑞公司 |
包含缀合荚膜糖抗原的免疫原性组合物及其用途
|
|
WO2024224266A1
(en)
|
2023-04-24 |
2024-10-31 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2024231727A1
(en)
|
2023-05-05 |
2024-11-14 |
Sanofi |
Compositions for use in treatment of acne
|
|
AR132662A1
(es)
|
2023-05-10 |
2025-07-16 |
Sanofi Sa |
Combinación de vacunas respiratorias de arnm
|
|
US20240398932A1
(en)
|
2023-05-11 |
2024-12-05 |
Sanofi Pasteur Inc. |
Respiratory syncytial virus vaccine and methods of use
|
|
WO2024241172A2
(en)
|
2023-05-19 |
2024-11-28 |
Glaxosmithkline Biologicals Sa |
Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
|
|
WO2024246358A1
(en)
|
2023-06-01 |
2024-12-05 |
Sanofi |
Thermostable compositions comprising mrna lipid nanoparticles
|
|
WO2025006737A1
(en)
|
2023-06-30 |
2025-01-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
|
|
AR133317A1
(es)
|
2023-07-19 |
2025-09-17 |
Sanofi Sa |
Constructos antigénicos de porphyromonas gingivalis
|
|
TW202527960A
(zh)
|
2023-09-06 |
2025-07-16 |
美商賽諾菲巴斯德公司 |
經修飾ｂ型流感血球凝集素多肽及核酸及其用途
|
|
TW202527906A
(zh)
|
2023-09-14 |
2025-07-16 |
美商輝瑞股份有限公司 |
包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
|
|
TW202535439A
(zh)
|
2023-11-17 |
2025-09-16 |
美商賽諾菲巴斯德公司 |
海藻糖疫苗調配物
|
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
|
WO2025163460A2
(en)
|
2024-01-30 |
2025-08-07 |
Pfizer Inc. |
Vaccines against respiratory diseases
|
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
US20250281605A1
(en)
|
2024-03-08 |
2025-09-11 |
Sanofi |
Antigenic Epstein Barr Virus Polypeptides
|
|
WO2025191415A1
(en)
|
2024-03-11 |
2025-09-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
|
|
WO2025210592A1
(en)
|
2024-04-05 |
2025-10-09 |
Sanofi Pasteur Inc. |
Muscle cell lnp-mrna quality control assays
|
|
WO2025219904A1
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
|
|
WO2025238502A1
(en)
|
2024-05-14 |
2025-11-20 |
Pfizer Inc. |
Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof
|